Levact (Bendamustine Hydrochloride)

• Bendamustine Hydrochloride is used in the management of hematologic malignancies that involve abnormal lymphocyte proliferation.
• Chronic lymphocytic leukemia: improves disease control, prolongs progression‑free survival, and can extend overall survival when administered as part of combination therapy.
• Non‑Hodgkin lymphoma: induces remission, reduces tumor burden, and enhances response rates across various aggressive and indolent subtypes when used intravenously.
• Mantle cell lymphoma: provides significant overall response rates and durable remissions in patients with relapsed or refractory disease, especially when combined with rituximab.

• Bendamustine is a bifunctional alkylating agent that forms covalent cross‑links between DNA strands, preventing DNA replication and transcription. The benzimidazole ring also interferes with cellular metabolism, contributing to cell‑cycle arrest. The cross‑linking preferentially affects cells in the S‑phase, while the metabolic inhibition reduces nucleotide synthesis, enhancing cytotoxicity, ultimately triggering apoptosis in rapidly dividing malignant lymphocytes.

Bendamustine Hydrochloride may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Fatigue: generalized tiredness affecting daily activities.
• Neutropenia: reduced neutrophil count increasing infection risk.

Serious or Rare Side Effects

• Severe infections: opportunistic or bacterial infections requiring hospitalization.
• Pulmonary toxicity: interstitial pneumonitis or acute respiratory distress.
• Anaphylaxis: immediate hypersensitivity with hypotension and airway compromise.

When using Levact, careful monitoring and specific precautions are recommended.

• Monitor blood counts: perform regular CBC to detect neutropenia, thrombocytopenia, and anemia.
• Assess infection risk: watch for fever or signs of infection and initiate prompt treatment.
• Evaluate liver function: check hepatic enzymes before and during therapy.
• Adjust for renal impairment: consider dose modification in patients with reduced clearance.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Bendamustine may interact with other medicines; awareness of potential interactions helps optimize safety.

Major Interactions (Avoid)

• Other alkylating chemotherapy agents: additive bone marrow suppression.
• Live attenuated vaccines: increased risk of infection.

Moderate Interactions (Monitor Closely)

• Strong CYP3A4 inhibitors (e.g., azole antifungals): may raise bendamustine plasma levels.
• Anticoagulants (e.g., warfarin): potential for enhanced bleeding.
• Granulocyte‑colony stimulating factor (G‑CSF) agents: may affect neutrophil recovery dynamics.